51,301 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Acquired by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC bought a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDITFree Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,301 shares of the company’s stock, valued at approximately $520,000. Campbell & CO Investment Adviser LLC owned 0.06% of Editas Medicine as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in EDIT. Russell Investments Group Ltd. lifted its stake in Editas Medicine by 401.9% in the fourth quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company’s stock valued at $53,000 after buying an additional 4,156 shares during the period. Clear Street Markets LLC acquired a new position in shares of Editas Medicine during the 3rd quarter valued at $44,000. Amalgamated Bank boosted its stake in Editas Medicine by 18.0% during the third quarter. Amalgamated Bank now owns 8,023 shares of the company’s stock worth $63,000 after acquiring an additional 1,226 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Editas Medicine by 351.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,450 shares of the company’s stock worth $96,000 after purchasing an additional 7,355 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in shares of Editas Medicine during the fourth quarter valued at about $111,000. Institutional investors own 71.90% of the company’s stock.

Insider Buying and Selling

In other news, Director Jessica Hopfield acquired 45,000 shares of Editas Medicine stock in a transaction on Monday, May 13th. The stock was acquired at an average cost of $5.64 per share, with a total value of $253,800.00. Following the completion of the acquisition, the director now owns 67,700 shares in the company, valued at $381,828. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Editas Medicine news, Director Jessica Hopfield bought 45,000 shares of the business’s stock in a transaction on Monday, May 13th. The stock was purchased at an average price of $5.64 per share, for a total transaction of $253,800.00. Following the completion of the transaction, the director now directly owns 67,700 shares of the company’s stock, valued at $381,828. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Gilmore Neil O’neill sold 12,191 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the sale, the chief executive officer now directly owns 315,279 shares in the company, valued at approximately $1,734,034.50. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by insiders.

Editas Medicine Trading Down 2.4 %

Shares of Editas Medicine stock opened at $5.30 on Monday. The firm has a market capitalization of $435.87 million, a P/E ratio of -2.52 and a beta of 2.06. The business’s fifty day simple moving average is $5.78 and its 200 day simple moving average is $7.86. Editas Medicine, Inc. has a 12 month low of $4.91 and a 12 month high of $11.91.

Editas Medicine (NASDAQ:EDITGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.13). The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $11.14 million. Editas Medicine had a negative return on equity of 47.34% and a negative net margin of 239.36%. The business’s quarterly revenue was down 88.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.71) EPS. Analysts predict that Editas Medicine, Inc. will post -2.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Morgan Stanley upgraded Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 target price for the company in a research note on Thursday, May 9th. Citigroup cut their target price on Editas Medicine from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. JPMorgan Chase & Co. boosted their price target on shares of Editas Medicine from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Barclays dropped their price objective on shares of Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 9th. Finally, StockNews.com downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, Editas Medicine has a consensus rating of “Hold” and a consensus price target of $13.27.

Read Our Latest Stock Analysis on Editas Medicine

Editas Medicine Profile

(Free Report)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

See Also

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDITFree Report).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.